Pure drug nanomedicines - where we are?
10.1016/S1875-5364(25)60851-X
- Author:
Yaoyao LAI
1
;
Bing XIE
1
;
Wanting ZHANG
1
;
Wei HE
2
Author Information
1. Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 2111198, China.
2. Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 2111198, China. Electronic address: weihe@cpu.edu.cn.
- Publication Type:Review
- Keywords:
Antibody-drug conjugates;
Drug nanocrystals;
Drug nanoparticles;
Drug-drug cocrystals;
Nanobodies;
Pure drug nanomedicines
- MeSH:
Nanomedicine;
Humans;
Nanoparticles/chemistry*;
Pharmaceutical Preparations/chemistry*;
Animals;
Drug Carriers/chemistry*
- From:
Chinese Journal of Natural Medicines (English Ed.)
2025;23(4):385-409
- CountryChina
- Language:English
-
Abstract:
Pure drug nanomedicines (PDNs) encompass active pharmaceutical ingredients (APIs), including macromolecules, biological compounds, and functional components. They overcome research barriers and conversion thresholds associated with nanocarriers, offering advantages such as high drug loading capacity, synergistic treatment effects, and environmentally friendly production methods. This review provides a comprehensive overview of the latest advancements in PDNs, focusing on their essential components, design theories, and manufacturing techniques. The physicochemical properties and in vivo behaviors of PDNs are thoroughly analyzed to gain an in-depth understanding of their systematic characteristics. The review introduces currently approved PDN products and further explores the opportunities and challenges in expanding their depth and breadth of application. Drug nanocrystals, drug-drug cocrystals (DDCs), antibody-drug conjugates (ADCs), and nanobodies represent the successful commercialization and widespread utilization of PDNs across various disease domains. Self-assembled pure drug nanoparticles (SAPDNPs), a next-generation product, still require extensive translational research. Challenges persist in transitioning from laboratory-scale production to mass manufacturing and overcoming the conversion threshold from laboratory findings to clinical applications.
